AIM ImmunoTechAIM -12.18%33 Days Payable is 32,450.78 as of Mar. 2026, which is 10962% above its 10-year median of 293.36. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.69 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 706 Biotechnology companies, AIM ImmunoTech ranks better than 95.89% on this metric.
The historical rank and industry rank for AIM ImmunoTech's Days Payable or its related term are showing as below:
AIM'
s Days Payable Range Over the Past 10 Years
Min: 124.74 Med: 293.36 Max: 75507.9
Current: 10972.74
During the past 13 years, AIM ImmunoTech's highest Days Payable was 75507.90. The lowest was 124.74. And the median was 293.36.
AIM's Days Payable is ranked better than 95.89% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs AIM: 10972.74
AIM ImmunoTech's Days Payable
declined
from Mar. 2025 (60,804.44) to Mar. 2026 (32,450.78).
It may suggest that AIM ImmunoTechaccelerated paying its suppliers.
AIM ImmunoTech Days Payable Related Terms
AIM ImmunoTech Days Payable Historical Data
* Premium members only.
The historical data trend for AIM ImmunoTech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AIM ImmunoTech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Days Payable distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
AIM ImmunoTech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM ImmunoTech (AIM) has a Days Payable of 32,450.78 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AIM ImmunoTech and its competitors. This is 10962% above median its historical median of 293.36. Over the past decade, AIM ImmunoTech's Days Payable has ranged from 124.74 to 75,507.90. According to the industry distribution chart, AIM ImmunoTech ranks #29 out of 706 companies in the Biotechnology industry, placing it in the top 4.1%.
Is AIM ImmunoTech's Days Payable too high?
AIM ImmunoTech's current Days Payable of 32,450.78 is 10962% above median its 10-year median of 293.36. Over the past 10 years, this metric has ranged from a low of 124.74 to a high of 75,507.90. The Biotechnology industry median Days Payable is 113.56. AIM ImmunoTech's value of 32,450.78 is 28475.9% above this industry median. Based on the distribution chart, AIM ImmunoTech ranks #29 out of 706 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Days Payable compare to BGMS and FBLG?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #29 out of 706 companies for Days Payable. This places AIM ImmunoTech in the top 4% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. AIM ImmunoTech's value of 32,450.78 is 28475.9% above this benchmark. Historically, AIM ImmunoTech's own Days Payable has ranged from 124.74 to 75,507.90 over the past decade. While the company's 10-year median is 293.36 vs. the industry median of 113.56, AIM ImmunoTech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AIM ImmunoTech's current Days Payable of 32,450.78 is 28475.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AIM ImmunoTech and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AIM ImmunoTech's current Days Payable is 32,450.78, which is 10962% above median its own 10-year median of 293.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.69, compared to a current price of $0.31 — trading 88.4% below its estimated fair value. The current Days Payable is 32,450.78, which is 10962% above median its 10-year median of 293.36 and 28475.9% above the Biotechnology industry median of 113.56. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Days Payable is 32,450.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM ImmunoTech (AIM) Overvalued in 2026?
Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued.
The current stock price of $0.31 is trading 88.4% below its estimated GF Value™ of $2.69.
GuruFocus considers AIM ImmunoTech to be Possible Value Trap.
Key valuation signals for AIM:
Days Payable: 32,450.78 (10962% above median its 10-year median of 293.36)
GF Value™: $2.69 vs. price of $0.31 (88.4% below fair value)
Industry Position: 28475.9% above the Biotechnology median (#29 of 706)
No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score
Get the complete analysis for AIM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIM has been successfully added to your 
